| Author | Pernaute-Lau, Leyre | |
| Author | Camara, Mahamadou | |
| Author | Sousa, Taís Nóbrega de | |
| Author | Morris, Ulrika | |
| Author | Ferreira, Marcelo Urbano | |
| Author | Gil, José Pedro | |
| Access date | 2023-01-02T18:25:31Z | |
| Available date | 2023-01-02T18:25:31Z | |
| Document date | 2022 | |
| Citation | PERNAUTE-LAU, Leyre et al. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malária. Expert Opin Drug Metab Toxicol., v. 18, n. 1, p. 39-59, 2022. doi: 10.1080/17425255.2022.2049235. | en_US |
| ISSN | 1742-5255 | en_US |
| URI | https://www.arca.fiocruz.br/handle/icict/56247 | |
| Language | eng | en_US |
| Publisher | Informa Healthcare | en_US |
| Rights | restricted access | |
| Title | An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malária | en_US |
| Type | Article | |
| Abstract | Introduction: Artemisinin-based combination therapies (ACTs) are recommended first-line antimalarials for uncomplicated Plasmodium falciparum malaria. Pharmacokinetic/pharmacodynamic variation associated with ACT drugs and their effect is documented. It is accepted to an extent that inter-individual variation is genetically driven, and should be explored for optimized antimalarial use.
Areas covered: We provide an update on the pharmacogenetics of ACT antimalarial disposition. Beyond presently used antimalarials, we also refer to information available for the most notable next-generation drugs under development. The bibliographic approach was based on multiple Boolean searches on PubMed covering all recent publications since our previous review.
Expert opinion: The last 10 years have witnessed an increase in our knowledge of ACT pharmacogenetics, including the first clear examples of its contribution as an exacerbating factor for drug-drug interactions. This knowledge gap is still large and is likely to widen as a new wave of antimalarial drug is looming, with few studies addressing their pharmacogenetics. Clinically useful pharmacogenetic markers are still not available, in particular, from an individual precision medicine perspective. A better understanding of the genetic makeup of target populations can be valuable for aiding decisions on mass drug administration implementation concerning region-specific antimalarial drug and dosage options. | en_US |
| Affilliation | Department of Microbiology. Tumor and Cell biology, Karolinska Institutet. Solna, Sweden/Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute. University of Lisbon. Lisbon, 1749-016, Portugal. | en_US |
| Affilliation | Department of Epidemiology of Parasitic Diseases. Faculty of Pharmacy. Malaria Research and Training Center. University of Science, Techniques and Technologies of Bamako. Bamako, Mali. | en_US |
| Affilliation | Molecular Biology and Malaria Immunology Research Group. René Rachou Institute. Oswaldo Cruz Foundation. Belo Horizonte, MG, Brasil. | en_US |
| Affilliation | Department of Microbiology. Tumor and Cell biology, Karolinska Institutet. Solna, Sweden. | en_US |
| Affilliation | Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute. University of Lisbon. Lisbon, 1749-016, Portugal/Department of Parasitology.Institute of Biomedical Sciences. University of São Paulo., São Paulo,SP, Brazil. | en_US |
| Affilliation | Department of Microbiology. Tumor and Cell biology, Karolinska Institutet. Solna, Sweden/Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute. University of Lisbon. Lisbon, 1749-016, Portugal/ Global Health and Tropical Medicine. Institute of Hygiene and Tropical Medicine. Nova University of Lisbon, Portugal. | en_US |
| Subject | ABC transporter | en_US |
| Subject | ACT | en_US |
| Subject | CYP | en_US |
| Subject | Malaria | en_US |
| Subject | adverse events | en_US |
| Subject | antimalarial drug | en_US |
| Subject | metabolism | en_US |
| Subject | pharmacogenetics | en_US |
| Embargo date | 2099-12-30 | |
